**VITRAKVI is for adult and pediatric patients with NTRK gene fusion-positive solid tumors.**

VITRAKVI is an oral medication that is not a chemotherapy.

VITRAKVI is the first medicine designed to block TRK fusion proteins
VITRAKVI is thought to work by blocking these proteins and stopping cancer cells from growing, but the exact way VITRAKVI works is unknown
VITRAKVI can work in a variety of tumor types as long as the tumor is caused by an NTRK gene fusion

Learn how VITRAKVI may help you

The #1 prescribed TRK^* inhibitor for NTRK gene fusion-positive solid tumors^a

What is VITRAKVI?

VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:

are caused by certain abnormal neurotrophic receptor tyrosine kinase (NTRK) genes and
have spread or if surgery to remove their cancer is likely to cause severe complications, and
there is no acceptable treatment option or the cancer grew or spread on other treatment.

Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.

Please select the option that best describes your interest.

Still Need to Test Your Cancer?

Learn about genomic testing and the NTRK biomarker’s role in cancer.

What Questions Should You Ask Your Doctor?

If you’re NTRK positive and considering VITRAKVI, the discussion guide can help you talk to your doctor.

I’m a VITRAKVI Patient or Caregiver and Want to Share My Story

We would love to hear your experience.

SEE REAL PATIENT STORIES

^*TRK, tropomyosin receptor kinase.

^aBased on medical claims and prescription data claims for the period January 2019 through January 2025. Validated by IQVIA in March 2025.

What is VITRAKVI?

VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:

are caused by certain abnormal neurotrophic receptor tyrosine kinase NTRK genes and
have spread or if surgery to remove their cancer is likely to cause severe complications, and
there is no acceptable treatment option or the cancer grew or spread on other treatment.

Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.

NTRK, neurotrophic receptor tyrosine kinase; TRK, tropomyosin receptor kinase.

Important Safety Information

VITRAKVI may cause serious side effects, including:

Central Nervous System (CNS) problems: VITRAKVI may cause dizziness, confusion, problems with concentration, attention, and memory, changes in your mood, and sleep problems. Tell your healthcare provider if you develop any of these symptoms or if they get worse.
Bone Fractures: Bone fractures can happen with VITRAKVI. Tell your healthcare provider if you develop pain, changes in your ability to move around, or bone abnormalities
Liver problems: Abnormal liver blood tests may occur with VITRAKVI and can sometimes become serious. Your healthcare provider will do blood tests to check your liver function before starting and during treatment with VITRAKVI as needed. Tell your healthcare provider right away if you develop new or worsening symptoms of liver problems including:

yellowing of skin or the white part of your eyes (jaundice)
dark or brown urine
pain in the upper right side of your stomach (abdomen)

bruising or bleeding more easily than normal
tiredness
nausea or vomiting
loss of appetite

Your healthcare provider may decrease your dose, temporarily stop or permanently stop your treatment with VITRAKVI if you develop serious side effects.

Before taking VITRAKVI, tell your healthcare provider about all of your medical conditions, including if you:

have liver problems
have nervous system (neurological) problems
are pregnant or plan to become pregnant. VITRAKVI can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with VITRAKVI or think you may be pregnant.
Females who are able to become pregnant:
- Your healthcare provider may do a pregnancy test before you start treatment with VITRAKVI.
- You should use effective birth control (contraception) during treatment and for 1 week after the last dose of VITRAKVI. Talk to your healthcare provider about birth control methods that may be right for you.
Males with female partners who are able to become pregnant:
- You should use effective birth control during treatment with VITRAKVI and for 1 week after the last dose of VITRAKVI.
are breastfeeding or plan to breastfeed. It is not known if VITRAKVI passes into your breast milk. Do not breastfeed during treatment and for 1 week after the last dose of VITRAKVI.

While on VITRAKVI, you should avoid:

VITRAKVI can make you feel dizzy. Do not drive or operate machinery until you know how VITRAKVI affects you.
Avoid taking St. John’s wort, eating grapefruit, or drinking grapefruit juice during treatment with VITRAKVI.

Tell your healthcare provider about all of the medicines you take, including prescription and over the counter (OTC) medicines, vitamins, and herbal supplements. Taking VITRAKVI with certain other medicines may affect the amount of VITRAKVI or other medicines in your blood and may cause side effects or affect the way that VITRAKVI works.

The most common side effects with VITRAKVI include:

increase in certain liver blood tests
low red blood cell and white blood cell counts
low levels of protein called albumin in the blood
muscle and bone pain
increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems)
low levels of calcium in the blood
tiredness
vomiting

cough
constipation
fever
diarrhea
nausea
stomach (abdomen) pain
dizziness
rash

VITRAKVI may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects with VITRAKVI. Call your healthcare provider for medical advice about side effects. You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

What is VITRAKVI?

VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:

are caused by certain abnormal neurotrophic receptor tyrosine kinase NTRK genes and
have spread or if surgery to remove their cancer is likely to cause severe complications, and
there is no acceptable treatment option or the cancer grew or spread on other treatment.

Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.

NTRK, neurotrophic receptor tyrosine kinase; TRK, tropomyosin receptor kinase.

For important risk and use information about VITRAKVI, please see the full Prescribing Information.

For Bayer products, you can report these directly to Bayer by clicking here.

© 2025 Bayer. Bayer, the Bayer Cross, and VITRAKVI are registered trademarks of Bayer, and TRAK Assist and VITRAKVI Commitment Program are trademarks of Bayer. All other trademarks are the property of their respective owners.

This site is intended for US audiences only.

Last updated on 06/2025